Results 121 to 130 of about 775,670 (354)

Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non–small cell lung cancer

Science immunology, 2020
EGFR inhibitor erlotinib synergizes with anti–PD-1 in a mouse model of lung adenocarcinoma. Giving anti–PD-1 a boost Anti–PD-1 therapy is ineffective in the context of EGFR-mutated lung adenocarcinomas (LUADs). Here, Sugiyama et al.
E. Sugiyama, Y. Togashi, Yoshiko Takeuchi, S. Shinya, Yasuko Tada, K. Kataoka, K. Tane, E. Sato, G. Ishii, K. Goto, Y. Shintani, M. Okumura, M. Tsuboi, H. Nishikawa   +13 more
semanticscholar   +1 more source

Kidney function in the very elderly with hypertension: data from the hypertension in the very elderly (HYVET) trial.

, 2013
BACKGROUND: numerous reports have linked impaired kidney function to a higher risk of cardiovascular events and mortality. There are relatively few data relating to kidney function in the very elderly. METHODS: the Hypertension in the Very Elderly Trial (
Beckett, Nigel, Bulpitt, Christopher, Burch, Lisa, Fagard, Robert, Fletcher, Astrid, Li, Mengying, Narkiewicz, Krzysztof, Nitsch, Dorothea, Peters, Ruth, Poulter, Ruth, Wang, Nan   +10 more
core   +1 more source

The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: A systematic review and meta-analysis [PDF]

, 2019
Background The brain is a common site for metastasis in non-small-cell lung cancer (NSCLC). This study was designed to evaluate the relationship between the mutational of the epidermal growth factor receptor (EGFR) and overall survival (OS) in NSCLC ...
Han, Yunan, Li, Wen-Ya, Liu, Xing-Yu, Miao, Zhi-Feng, Song, Yong-Xi, Wang, Zhen-Ning, Wu, Jian-Hua, Xu, Hao, Xu, Hui-Mian, Xu, Ying-Ying, Yin, Song-Cheng, Zhao, Ting-Ting   +11 more
core   +2 more sources

Quantitative proteomic analysis reveals different characteristics of bladder cancer cells after exposure to bisphenol A

FEBS Open Bio, EarlyView.
Bisphenol A (BPA), a common chemical in plastics, exerts dual effects on bladder cancer cells: low doses promote growth and migration, while high doses suppress growth and migration. Multi‐omics and bioinformatics reveal BPA acts via MAPK and inflammatory pathways.
Shaomin Niu, Lanlan Li, Wenjuan Jia, Hanzhong Feng, Xiaoquan Yu, Youli Zhao, Fengzhi Yuan, Hui Ding, Junqiang Tian, Yong‐Xing He, Zhiping Wang   +10 more
wiley   +1 more source

Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma. [PDF]

, 2017
Cross-talk among oncogenic signaling and metabolic pathways may create opportunities for new therapeutic strategies in cancer. Here we show that although acute inhibition of EGFR-driven glucose metabolism induces only minimal cell death, it lowers the ...
A Magi, AM Spence, Anthony Letai, AV Follis, AV Vaseva, BA Tannous, BJ Altman, Brian Higgins, C Tovar, CW Brennan, D Jiang, D Nathanson, DA Nathanson, DA Reardon, David A Nathanson, DR Green, E Cerami, E Strom, E Tasdemir, EH Cheng, EQ Lee, G Lessene, H Dai, H Takanaga, Harley I Kornblum, I Babic, I Vivanco, J Deng, J Gao, J Lee, J Lehár, J Montero, J Pomerantz, Jason T Lee, JC Liu, JE Chipuk, JE Chipuk, JE Chipuk, JIJ Leu, Jonathan E Tsang, JP Kruse, K Masui, L Qu, Laura Gosa, Lisa Ta, M Mihara, M-K Han, MG Vander Heiden, Mitra Dehghan Harati, MJ Lee, Nicholas A Bayley, OD Maddocks, P Nagesh Rao, Paul S Mischel, Peter M Clark, PM Clark, PY Wen, Q Ding, R Haq, RGW Verhaak, RJ DeBerardinis, Steven J Bensinger, TF Cloughesy, Timothy F Cloughesy, Veerle W Daniels, W Blake Gilmore, W Wei, WH Yang, William H Yong, Wilson X Mai, Y Zhang, Y Zhao   +71 more
core   +1 more source

Identifying gene expression signatures for risk stratification of postoperative adjuvant chemotherapy in colorectal cancer

FEBS Open Bio, EarlyView.
A novel signature integrating genome‐wide analysis with clinical factors predicts recurrence in stage II colorectal cancer and enables a new risk stratification to guide postoperative adjuvant chemotherapy. Clinical risk stratification for postoperative recurrence in patients with pathological stage II (pStage II) colorectal cancer (CRC) is essential ...
Mayuko Otomo, Keisuke Okuno, Shuichi Watanabe, Sakiko Oba, Hiroyasu Kagawa, Masanori Tokunaga, Daisuke Ban, Yusuke Kinugasa   +7 more
wiley   +1 more source

Fluorescein- and EGFR-Antibody Conjugated Silica Nanoparticles for Enhancement of Real-time Tumor Border Definition Using Confocal Laser Endomicroscopy in Squamous Cell Carcinoma of the Head and Neck

Nanomaterials, 2019
Intraoperative definition of tumor free resection margins in head and neck cancer is challenging. In the current proof-of-principle study we evaluated a novel silica nanoparticle-based agent for its potential use as contrast enhancer.
Anna Watermann, Rita Gieringer, Anna-Maria Bauer, Sven Kurch, Ralf Kiesslich, Wolfgang Tremel, Jan Gosepath, Juergen Brieger   +7 more
doaj   +1 more source

Case report: EGFR fusion mutation combined with EGFR amplification responds to EGFR-TKI therapy

Frontiers in Oncology
Given their good antitumor effects, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard first-line therapy for EGFR-sensitive mutations, including exon 19 deletions and exon 21 L858R mutations. EGFR fusion mutations and EGFR amplification are very rare in non-small cell lung cancer (NSCLC). We describe 2 patients with
Zhulin Wang, Zhulin Wang, Chunyao Huang, Wenbo Fan, Shaowu Sun, Kaiyuan Li, Xu Liu, Jiangtao Pu, Guoqing Zhang, Xiangnan Li   +9 more
openaire   +3 more sources

Acquired Resistance Mutations to EGFR Treatment in Non-Small Cell Lung Cancer [PDF]

, 2018
Non-small cell lung cancer (NSCLC) is currently the number one cause of cancer death in the United States for both men and women.1 Mutations in the epidermal growth factor receptor (EGFR) gene are detected in approximately 30% of individuals with ...
Omerza, PhD, Gregory, Schoenberg, Benjamen   +1 more
core   +1 more source

VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research [PDF]

, 2016
Accurate variant calling in next generation sequencing (NGS) is critical to understand cancer genomes better. Here we present VarDict, a novel and versatile variant caller for both DNA- and RNA-sequencing data.
Ahdesmaki, Miika, Barrett, J. Carl, Chapman, Brad, Dougherty, Brian, Dry, Jonathan R., Hofmann, Oliver, Johnson, Justin, Lai, Zhongwu, Markovets, Aleksandra, McEwen, Robert   +9 more
core   +2 more sources